A person's suitability for<unk>  is decided by the person's anatomy and the surgeon.<unk>  is generally more suitable for younger people who are not morbidly obese, are clinically qualified for a<unk>  replacement (determined by the doctor), have been diagnosed with noninflammatory degenerative joint disease, do not have an infection, and are not allergic to the metals used in the implant. The potential advantages of<unk>  compared to THR include less bone removal (bone preservation), a reduced chance of<unk>  dislocation due to a relatively larger femoral head size (given that the person has an anatomically correct femoral head size), and easier revision surgery for any subsequent revision to a THR device because a surgeon will have more original bone stock available.<unk>  has the potential of being a solution for life, allows a normal ROM (range of movement) and minimizes the amount of "stress shielding", compared with THR. Since the femoral neck is retained and the femoral cavity with its marrow not opened up two other advantages exist, namely no risk of blood clots by fatty marrow that can enter the blood stream with the THR procedure and no risk of introducing bacteria in the opened femoral canal resulting in a deep infection as can happen with the THR procedure. The potential disadvantages of<unk>  are femoral neck fractures (rate of 0–4%), aseptic loosening, and metal wear. Due to the retention of the person's complete femoral neck other advantages exist: Surgeon induced discrepancies in leg length (as could happen with THR) are now minimized. Also, the toe-in or toe-out faults that could occur interoperatively with THR are now over because the femoral neck that determines foot direction is left undisturbed with<unk> . On February 10, 2011, the U.S. FDA issued a patient advisory on metal-metal<unk>  implants, stating it was continuing to gather and review all available information about metal-on-metal<unk>  systems. On June 27–28, 2012, an advisory panel met to decide whether to impose new standards. No new standards, such as routine checking of blood metal ion levels, were set, but guidance was updated. According to the Australian Orthopaedic Associate National Joint Replacement Registry (AOANJRR) 2018 Annual Report,<unk>  (total)<unk>  is overwhelmingly used for males (98% of total<unk> <unk>  replacement were males), and has declined in popularity since the mid-2000s (the number of total<unk>  procedures in 2017 was 78.7% less than 2005). In 2006, the United States FDA approved<unk>  using the Birmingham<unk>  (BHR) system, designed by British Orthopaedic surgeon Derek McMinn. All other FDA approved devices have been removed from the US Market. The BHR is no longer suggested for use in women. There are several other manufacturers of<unk>  systems, mainly in Europe.
Hip resurfacing
Finger joint replacement
Ankle replacement
High tibial osteotomy
Heel lift
Hip replacement
Reverse shoulder replacement
Ulnar collateral ligament reconstruction